DNA interactions of new cytotoxic tetrafunctional dinuidear platinum complex trans,trans-[{PtCl2(NH3)}(2)(piperazine)]

Publikace: BIOCHEMICAL PHARMACOLOGY 73, 1887-1900 Autoři: Brabec, V., Christofis, P., Slamova, M., Kostrhunova, H., Novakova, O., Najajreh, Y., Gibson, D., Kagparkova, J. Rok: 2007

Abstrakt

A new tetrafunctional dinuclear platinum complex trans,tTayis-[{PtCl2(NH3)}(2)(piperazine)] with sterically rigid linking group was designed, synthesized and characterized. In this novel molecule, the DNA-binding features of two classes of the platinum compounds with proven antitumor activity are combined, namely trans oriented bifunctional mononuclear platinum complexes with a heterocyclic ligand and polynuclear platinum complexes. DNA-binding mode of this new complex was analyzed by various methods of molecular biology and biophysics. The complex coordinates DNA in a unique way and interstrand and intrastrand cross-links are the predominant lesions formed in DNA in cell-free media and in absence of proteins. An intriguing aspect of trans trans- [{PtCl2(NH3)}(2)(piperazine)] is that, using a semi-rigid linker, interstrand cross-linking is diminished relative to other dinuclear platinum complexes with flexible linking groups and lesions that span several base pairs, such as tri- and tetrafunctional adducts, become unlikely. in addition, in contrast to the inability of trans,trans- [{PtCl2(NH3)}(2)(piperazine)] to cross-link two DNA. duplexes, the results of the present work convincingly demonstrate that this dinuclear platinum complex forms specific DNA lesions which can efficiently cross-link proteins to DNA. The results substantiate the view that trans,trans-[{PtCl2(NH3)}(2)(piperazine)] or its analcgues could be used as a tool for studies of DNA properties and their interactions or as a potential antitumor agent. The latter view is also corroborated by the observation that trans,trans[{PtCl2(NH3)}(2)(piperazine)] is a more effective cytotoxic agent than cisplatin against human tumor ovarian cell lines. (c) 2007 Elsevier Inc. All rights reserved.